BerGenBio ASA
OSE:BGBIO.OL
0.152 (NOK) • At close November 17, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) NOK.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0.354 | 0.389 | 0.774 | 0.601 | 8.9 | 2.335 | 0 | 0 | 0 | 0.598 |
| Cost of Revenue
| 84.278 | 0 | 0 | 89.469 | 65.25 | 66.493 | 0.193 | 0.207 | 0.179 | 0 |
| Gross Profit
| -83.924 | 0.389 | 0.774 | -88.868 | -56.35 | -64.158 | -0.193 | -0.207 | -0.179 | 0.598 |
| Gross Profit Ratio
| -237.073 | 1 | 1 | -147.867 | -6.331 | -27.477 | 0 | 0 | 0 | 1 |
| Reseach & Development Expenses
| 107.786 | 8.34 | 12.744 | 21.792 | 21.225 | 10.29 | 12.519 | 17.039 | 4.632 | 5.688 |
| General & Administrative Expenses
| 0 | 0 | 12.744 | 21.792 | 21.225 | 10.29 | 12.519 | 17.039 | 4.632 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 3.727 | 105.057 | 12.744 | 21.792 | 21.225 | 10.29 | 12.519 | 17.039 | 4.632 | 0 |
| Other Expenses
| 84.387 | 297.684 | 289.748 | 218.109 | 170.825 | 186.584 | 171.189 | 0.001 | 0 | 0.001 |
| Operating Expenses
| 192.173 | 306.024 | 315.236 | 261.693 | 213.275 | 196.874 | 183.708 | 131.57 | 72.925 | 59.422 |
| Operating Income
| -191.819 | -305.635 | -314.464 | -261.091 | -204.374 | -194.539 | -183.708 | -131.57 | -72.925 | -58.824 |
| Operating Income Ratio
| -541.862 | -785.694 | -406.284 | -434.428 | -22.963 | -83.314 | 0 | 0 | 0 | -98.368 |
| Total Other Income Expenses Net
| 1.418 | 3.513 | 5.1 | 4.062 | 5.096 | 2.792 | 1.5 | 1.771 | 0.818 | 1.044 |
| Income Before Tax
| -190.401 | -302.122 | -309.364 | -257.029 | -199.278 | -191.747 | -182.208 | -129.799 | -72.107 | -57.78 |
| Income Before Tax Ratio
| -537.856 | -776.663 | -399.695 | -427.669 | -22.391 | -82.119 | 0 | 0 | 0 | -96.622 |
| Income Tax Expense
| 1.996 | -3.513 | 0.053 | 0.032 | 0.109 | 2.839 | 1.531 | 1.796 | 1.076 | 2.305 |
| Net Income
| -190.401 | -298.609 | -309.417 | -257.061 | -199.387 | -191.747 | -182.208 | -129.799 | -72.107 | -57.78 |
| Net Income Ratio
| -537.856 | -767.632 | -399.764 | -427.722 | -22.403 | -82.119 | 0 | 0 | 0 | -96.622 |
| EPS
| -13.3 | -38.65 | -40.36 | -39.37 | -38.76 | -40.6 | -45.19 | -29.44 | -16.35 | -13.11 |
| EPS Diluted
| -13.3 | -38.65 | -40.36 | -39.37 | -38.76 | -40.6 | -45.19 | -29.44 | -16.35 | -13.11 |
| EBITDA
| -189.6 | -300.918 | -307.999 | -256.271 | -198.384 | -191.496 | -181.984 | -129.567 | -71.67 | -56.34 |
| EBITDA Ratio
| -535.593 | -773.568 | -397.932 | -426.408 | -22.29 | -82.011 | 0 | 0 | 0 | -94.214 |